Evidence map›Paper›PMID 27617337›Full record

ArticlePathology oncology research : POR2017

Alpha-1-Antitrypsin Antagonizes Cisplatin-Induced Cytotoxicity in Prostate Cancer (PC3) and Melanoma Cancer (A375) Cell Lines.

Mila Ljujic, Sanja Mijatovic, Mirna Z Bulatovic, Marija Mojic, Danijela Maksimovic-Ivanic, Dragica Radojkovic, Aleksandra Topic

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mila LjujicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, Belgrade, 11221, Serbia.
Sanja MijatovicInstitute for Biological Research "Sinisa Stankovic", University of Belgrade, Bulevar despota Stefana 142, Belgrade, 11060, Serbia.
Mirna Z BulatovicInstitute for Biological Research "Sinisa Stankovic", University of Belgrade, Bulevar despota Stefana 142, Belgrade, 11060, Serbia.
Marija MojicInstitute for Biological Research "Sinisa Stankovic", University of Belgrade, Bulevar despota Stefana 142, Belgrade, 11060, Serbia.
Danijela Maksimovic-IvanicInstitute for Biological Research "Sinisa Stankovic", University of Belgrade, Bulevar despota Stefana 142, Belgrade, 11060, Serbia.
Dragica RadojkovicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, Belgrade, 11221, Serbia.
Aleksandra TopicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, Belgrade, 11221, Serbia. aleksandra.topic1@gmail.com.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased circulating alpha-1-antitrypsin (AAT) correlates with cancer stage/aggressiveness, but its role in cancer biology is unclear. We revealed antagonistic effect of AAT to cisplatin-induced cytotoxicity in prostate (PC3) and melanoma (A375) cancer cell lines. Moreover, AAT abrogated cytotoxicity of MEK inhibitor U0126 in PC3 cell line. Weaker antagonistic effect of AAT on cytotoxicity of PI3/Akt and NF-kB inhibitors was also observed. In addition, cisplatin increased AAT gene expression in transfected PC3 cells. However, AAT derived from transfected PC3 cells did not antagonize cisplatin-induced cytotoxicity. In conclusion, these results suggest possible association between high circulating AAT and cisplatin resistance.

Indexed as

alpha 1-AntitrypsinCell Line, TumorCisplatinHumansMaleMelanomaNF-kappa BPhosphatidylinositol 3-KinasesProstatic NeoplasmsProto-Oncogene Proteins c-aktSignal Transductionalpha 1-AntitrypsinCisplatinNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAlpha-1-antitrypsinCisplatinMelanoma cancerProstate cancer

Identifiers

PMID27617337
OpenAlexW2517492921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.